In this issue:
MSK clinical calculator for prognostication of locally advanced rectal cancer
RAINBOW-Asia: second-line ramucirumab + paclitaxel for gastric cancer
NIFTY: second-line liposomal irinotecan combination for biliary cancer
Temozolomide for grade 3 gastroenteropancreatic NENs
Rates of genetic testing for pancreatic cancer improved by in-clinic testing station
Anti-PD-L1 antibody has activity in PD-(L)1 inhibitor-naïve MSI-H/dMMR tumours
TAS-116 + nivolumab for colorectal cancer and other solid tumours
Osimertinib active in T790M-positive EGFR-TKI-resistant NSCLC
Neoadjuvant chemotherapy may improve survival in high-risk resectable CRLM
MMR status not prognostic in gastric/GOJ cancer treated with chemotherapy
Please login below to download this issue (PDF)